Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

FHS
June 29, 2023
10:24 am

Researchers performed a double-blinded, placebo-controlled phase III randomized clinical trial (RCT).

Sustainable weight loss with personalized semaglutide dosing

New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits of giving personalised doses of

May 14, 2024

Will MDMA Rejection Cast a Chill on Psychedelic Research?

The future of psychedelic research was dealt its biggest setback in years after the FDA declined to approve midomafetamine (MDMA) capsules for post-traumatic stress disorder

August 27, 2024

Australian study shows combined genomic screening for major hereditary diseases is cost-effective and health-saving

In an Australian study published in EClinicalMedicine, researchers evaluated the impact of a combined genomic screening program for hereditary breast and ovarian cancer, Lynch syndrome,

November 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.